biOasis Technologies Inc. (the “Company”) (TSX.V: “BTI”) announces that it has appointed Mahesh Kamat as an associate and lead blogger for the Company.
Before joining the biOasis team, Mahesh worked on the development and commercialization of biomarker-based assays for retinal disease treatments. He received his Masters in Biomedical Engineering from Drexel University, Pennsylvania and his MBA in international Business from Seattle University, Washington.
“The assignment is complex”, says CEO Rob Hutchison, “and we wanted someone who really understands the space, not just what we’re doing, but rather an objective point of view that aggregates the overabundance of information out their that surrounds our research and puts it into context.”
The company’s objective is to build a resource of focused, timely informational blogs, that investors, stakeholders and the greater biotech community can get unbiased information on what is going on in research and therapy development for Alzheimer’s and other Neurological Diseases.
Kim Elton, Communications Officer for biOasis said of Mahesh, “We looked long and hard for a guy with his combination of expertise, experience and communication skills and we’re very pleased with the quality of the content.”
ABOUT MAHESH KAMAT:
Mahesh is an Associate with biOasis Technologies as its lead blogger and is deeply motivated by the opportunity to bring innovative life-saving technologies to the market. He believes that through sound business strategies and innovative scientific accomplishments, we can solve all our pressing unmet medical needs. As a member of the biOasis team, he is excited to give a honest and unbiased perspective on the ever-progressing evolution of neurological disease treatments.
|
|
OTHER CONTRIBUTORS ARE:
Henry Baum, is a California based copywriter who’s written extensively about finances and investment – with a special emphasis on investing during an economic downturn. He has written for such sites as MoneySmartLife.com, ExpertsonCredit.com, and iStockAnalyst.com, as well as content for a long list of ecommerce niches: real estate, marketing, debt, insurance, health products, and other topics.
Christine Jones, a Seattle native and graduate of the University of Washington, is a major in English literature and microbiology. Her technical writing is in a number of areas of medicine, including neurology, HIV/AIDS, oncology and bleeding disorders.
ABOUT BIOASIS:
biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases. It has extensive and comprehensive intellectual property (“IP”) which it obtained from the University of British Columbia. The Company’s initial area of focus will be on the utilization of the IP to pursue a biomarker for the diagnosis of Alzheimer’s disease. The IP has been corroborated in double blinded and successive multi-site clinical trials.
According to the Centers for Disease Control and Prevention (“CDC”), Alzheimer’s disease was listed as the “underlying cause of death” for 65,829 Americans in 2004. It was the seventh leading cause of death for people of all ages and the fifth leading cause of death in people age 65 and older.
To find out more about biOasis Technologies Inc. visit .
On Behalf of the Board of Directors
“Robin Hutchison”
Director and CEO
(604) 542-5059
rob@bioasis.ca
“The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.”
|
